Cargando…

LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy

Detalles Bibliográficos
Autores principales:	Amati, Francesca, Diano, Laura, Vecchione, Lucia, Norata, Giuseppe Danilo, Koyama, Yoshikazu, Cutuli, Lucia, Catapano, Alberico Luigi, Romeo, Francesco, Ando, Hironori, Novelli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528301/ https://www.ncbi.nlm.nih.gov/pubmed/23212297 http://dx.doi.org/10.1038/mtna.2012.45

Ejemplares similares

LOX-1, OxLDL, and Atherosclerosis
por: Pirillo, Angela, et al.
Publicado: (2013)

Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population
por: Predazzi, Irene Marta, et al.
Publicado: (2012)

Molecular Mechanisms Responsible for the Antiinflammatory and Protective Effect of HDL on the Endothelium
por: Norata, Giuseppe D, et al.
Publicado: (2005)

Pro-oncogenic action of LOX-1 and its splice variant LOX-1Δ4 in breast cancer phenotypes
por: Pucci, Sabina, et al.
Publicado: (2019)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

High density lipoproteins and atherosclerosis: emerging aspects
por: Sala, Federica, et al.
Publicado: (2012)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

The conditional KO approach: Cre/Lox technology in human neurons
por: Patzke, Christopher, et al.
Publicado: (2016)

Functional Analysis and Molecular Dynamics Simulation of LOX-1 K167N Polymorphism Reveal Alteration of Receptor Activity
por: Biocca, Silvia, et al.
Publicado: (2009)

LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies
por: Rizzacasa, Barbara, et al.
Publicado: (2017)

Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
por: Bonacina, Fabrizia, et al.
Publicado: (2013)

Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis
por: Baragetti, Andrea, et al.
Publicado: (2021)

HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
por: Bonacina, Fabrizia, et al.
Publicado: (2021)

Hif1α down-regulation is associated with transposition of great arteries in mice treated with a retinoic acid antagonist
por: Amati, Francesca, et al.
Publicado: (2010)

Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides
por: Hinrich, Anthony J, et al.
Publicado: (2016)

Augmentation of protective immune responses against viral infection by oral administration of schizophyllan
por: Itoh, Wataru
Publicado: (1997)

Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
por: Kim, Young Jin, et al.
Publicado: (2022)

Production of schizophyllan from distiller’s dried grains with solubles by diverse strains of Schizophyllum commune
por: Sutivisedsak, Nongnuch, et al.
Publicado: (2013)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

The human rs1050286 polymorphism alters LOX‐1 expression through modifying miR‐24 binding
por: Morini, Elena, et al.
Publicado: (2015)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Conditional mutagenesis by oligonucleotide-mediated integration of loxP sites in zebrafish
por: Burg, Leonard, et al.
Publicado: (2018)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement
por: Batista-Duharte, Alexander, et al.
Publicado: (2020)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_omo48e5pr5runtpic5b3esjnll